Conjunctivitis Market
Economic Reaction to Sales of Allergic Conjunctivitis Therapeutics Featuring the Regional Outlook
Conjunctivitis Market by Type, Treatment & Region - Forecast 2022 - 2032
Conjunctivitis Market Outlook (2022-2032)
[333 Pages Report] The global conjunctivitis market size is expected to be worth US$ 1,825.8 Mn in 2022. The market is expected to reach US$ 3,208.7 Mn by 2032, growing at a 5.8% CAGR from 2022 to 2032. The factors responsible for growth are:
- One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations.
- Another factor that is likely to drive the global market over the projected period is the rise in the incidence of sexually transmitted diseases (STDs).
- A few risk factors for newborn conjunctivitis include things like unsanitary living situations, early births, and maternal STDs.
- During the projected period, the global conjunctivitis market is anticipated to be constrained by factors such as low illness awareness and inadequate pharmaceutical coverage in developing nations.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.
|
Report Attribute |
Details |
|
Conjunctivitis Market Value (2022) |
US$ 1825.8 Million |
|
Conjunctivitis Market Anticipated Value (2032) |
US$ 3208.7 Million |
|
Conjunctivitis Projected Growth Rate (2022-2032) |
5.8% |
Let us know your requirement to get
100% FREE customization
Factors Responsible for High Growth Rate in Asia Pacific Conjunctivitis Market
Due to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region, the Asia Pacific conjunctivitis market is anticipated to develop at the highest CAGR during the forecast period. Conjunctivitis is quite prevalent in nations like India. For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies. The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.
The emergence of cost-effective generic drugs is probably going to severely impede market expansion. Due to an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment. Over the anticipated time, these factors boost market expansion in the region.
The market share of the other regions, including Latin America, the Middle East, and Africa, was relatively smaller throughout the projection period. According to epidemiological research, for example, the incidence of ocular allergy in Mexico is estimated to be at 16.7%. Particularly noticeable in tropical or warm settings is this high frequency of ocular allergies.
Innovations and Developments to Aid Pharma Companies to Capture Larger Market Share
Pharmaceutical companies are developing new options for treating conjunctivitis while evaluating how well they relieve ocular irritation. Large pharmaceutical companies are funding all of this research. These factors are promoting the expansion of the global market for conjunctivitis treatment. Due to the increased illness awareness and increased global healthcare spending, the conjunctivitis market is expected to alter over the forecast period, allowing medication producers to extend their share.
Companies and academics are striving to evaluate obstacles and look for possibilities that might have an impact on bacterial conjunctivitis research and development. The focus of the currently being developed therapies is on cutting-edge methods to cure or ameliorate the state of illness. However, it is anticipated that these regions are likely to see development in the future owing to the expanded market presence of well-known brands and the high prevalence of ocular allergies there.
Additionally, companies like Sun Pharmaceuticals and Alembic Pharmaceuticals Limited are expanding their market share globally by concentrating on product approvals and the introduction of generic versions of already available medications. Moreover, startups like Ocular Therapeutix, Inc. and Eton Pharmaceutical are also working to secure regulatory clearances for their pipeline candidates, which is anticipated to help them boost their profits during the projection period.
The global market share of conjunctivitis is predicted to rise owing to fast-growing technological advancement, expanding geriatric population, growing disease prevalence, and surging demand for effective drug types. These are all responsible for fueling the growth of the global market of this industry.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystGrowing Air Pollution – A Key Reason for Market Growth
The global conjunctivitis market is motivated by increasing air pollution in the majority of cities across the world. The National Center for Biotechnology Information (NCBI) published a research study in 2016 that the critical reasons for the occurrence and worsening of allergic conjunctivitis are ambient air pollution and weather changes. This accredited to the conjunctiva being sensitive to environmental particles coupled with direct contact of the conjunctiva with the external environment. Therefore, an increase in air pollution promotes the growth of the global conjunctivitis treatment market.
Increasing Awareness Results in Market Growth
Increased awareness about allergic conjunctivitis amongst the medical community, patients, and individuals associated with patients is one of the key market driving factors responsible for the growth of the conjunctivitis market. Developing lifestyle and overall growth in the number of patients suffering from allergic conjunctivitis are primary factors boosting the growth of the market. Many biopharmaceutical companies plan to invest in research and development initiatives to develop new drugs and therapies for treating ocular disorders. Recently, the increasing awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Nearly 80 million North Americans Suffer from Ocular Allergy
The North American market is anticipated to dominate the global conjunctivitis market share over the forecast period. FMI analysts predict that by 2022, the regional conjunctivitis market will bloom with a revenue share of over 27%.
North America is the biggest market due to the increasing prevalence of allergic conjunctivitis in this region. An estimate says that nearly 70 to 80 million Americans suffer from ocular allergy. There is greater awareness of ophthalmic allergies in the region. This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth. A country like the United States has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.
Why is Europe a Promising Market?
Europe is accountable for a 22% market share in the global conjunctivitis market. The emergence as the second-largest regional market owing to the growing potential patient population in the region along with the growing use of sophisticated drugs. For example, based on the British Journal of Ophthalmology, in the United Kingdom, seasonal allergic conjunctivitis is a widespread and one of the mild forms of allergic conjunctivitis. It accounts for 25 to 50 per cent of all ocular allergy cases, and it is predicted to affect between 10 to 15 per cent of the population in the UK.
Start-ups Grazing the Ocular Disorders Market
- In March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company aims on creating an inventive ophthalmic therapy to enhance vision for individuals across the globe. The company announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF, which is a topical preservative-free ophthalmic solution for treating presbyopia.
- In October 2021, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop innovative genomic medicines using CRISPR/Cas9 technology for treating ocular diseases.
Key Players Benchmarking the Conjunctivitis Market
Some of the key players in the conjunctivitis market are Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Atopix Therapeutics Ltd., Novartis AG, Ocular Therapeutix, Inc., Bausch & Lomb Inc., Akorn Incorporated., Auven Therapeutics, Sirion Therapeutics, Inc., Sun Pharma Advanced Research Company Ltd., C Boehringer Ingelheim International GmbH., IBA Vision Ophthalmics, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd.
| Who | Bausch & Lomb Inc. |
| When | May 2022 |
| Strategic Move | Bausch + Lomb Corporation – a leading eye health company launched as a publicly traded company focused on protecting and improving the gift of sight for millions of people around the globe when it started trading under the BLCO symbol on the New York Stock Exchange and Toronto Stock Exchange. |
| Who | Sanofi-Aventis |
| When | August 2022 |
| Strategic Move | Sanofi and Innovent Biologics collaborated to bring innovative medicines to patients in China with difficult-to-treat cancers. Both companies are committed to accelerate the development and commercialization of two Sanofi key clinical stage oncology assets. Moreover, besides the agreement and collaboration, Sanofi will invest €300 million in Innovent through subscription of novel common shares. |
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.8% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments of the Conjunctivitis Market
By Type:
- Giant Papillary Conjunctivitis
- Seasonal Allergic Conjunctivitis
- Vernal Keratoconjunctivitis
- Contact Conjunctivitis
- Perennial Conjunctivitis
- Atopic Keratoconjunctivitis
By Treatment:
- Mast Cell Stabilizers
- Decongestant
- Immunotherapy
- Antihistamines
- Non-steroidal Anti-Inflammatory Drugs
- Olopatadine
- Epinastine
- Ointments
- Others
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
The growth outlook for the conjunctivitis market is predicted to advance at a CAGR of 5.8% from 2022 to 2032.
The North American region is anticipated to lead the conjunctivitis market during the forecast period.
The conjunctivitis market is likely to hold a valuation of US$ 3208.7 million by 2032.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Type Of Allergy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Type Of Allergy, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type Of Allergy, 2022-2032
5.3.1. Acute Allergic Conjunctivitis
5.3.2. Chronic Allergic Conjunctivitis
5.4. Y-o-Y Growth Trend Analysis By Type Of Allergy, 2017-2021
5.5. Absolute $ Opportunity Analysis By Type Of Allergy, 2022-2032
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032
6.3.1. Antihistamines
6.3.2. Vasoconstrictors
6.3.3. Mast Cell Stabilizers
6.3.4. Non-Steroidal Anti-Inflammatory Drugs
6.3.5. Corticosteroids
6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Type Of Allergy
8.2.3. By Drug Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type Of Allergy
8.3.3. By Drug Type
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type Of Allergy
9.2.3. By Drug Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type Of Allergy
9.3.3. By Drug Type
9.4. Key Takeaways
10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type Of Allergy
10.2.3. By Drug Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type Of Allergy
10.3.3. By Drug Type
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. India
11.2.1.5. Malaysia
11.2.1.6. Singapore
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of APAC
11.2.2. By Type Of Allergy
11.2.3. By Drug Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type Of Allergy
11.3.3. By Drug Type
11.4. Key Takeaways
12. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Type Of Allergy
12.2.3. By Drug Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type Of Allergy
12.3.3. By Drug Type
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Type Of Allergy
13.1.2.2. By Drug Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Type Of Allergy
13.2.2.2. By Drug Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Type Of Allergy
13.3.2.2. By Drug Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Type Of Allergy
13.4.2.2. By Drug Type
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Type Of Allergy
13.5.2.2. By Drug Type
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Type Of Allergy
13.6.2.2. By Drug Type
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Type Of Allergy
13.7.2.2. By Drug Type
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Type Of Allergy
13.8.2.2. By Drug Type
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Type Of Allergy
13.9.2.2. By Drug Type
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Type Of Allergy
13.10.2.2. By Drug Type
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Type Of Allergy
13.11.2.2. By Drug Type
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Type Of Allergy
13.12.2.2. By Drug Type
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Type Of Allergy
13.13.2.2. By Drug Type
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Type Of Allergy
13.14.2.2. By Drug Type
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Type Of Allergy
13.15.2.2. By Drug Type
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Type Of Allergy
13.16.2.2. By Drug Type
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Type Of Allergy
13.17.2.2. By Drug Type
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Type Of Allergy
13.18.2.2. By Drug Type
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Type Of Allergy
13.19.2.2. By Drug Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type Of Allergy
14.3.3. By Drug Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Boehringer Ingelheim GmbH
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Allergan Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Sanofi-Aventis
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Novartis AG
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Bausch & Lomb Inc
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. CIBA Vision Ophthalmics
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Pfizer Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Merck & Co., Inc
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Santen Pharmaceuticals Co. Ltd
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Alcon
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 3: Global Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Table 4: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 5: North America Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 6: North America Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: Latin America Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 9: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 11: Europe Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 12: Europe Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 17: MEA Market Value (US$ Mn) Forecast by Type Of Allergy, 2017-2032
Table 18: MEA Market Value (US$ Mn) Forecast by Drug Type, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 3: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 8: Global Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 9: Global Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 10: Global Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 13: Global Market Attractiveness by Type Of Allergy, 2022-2032
Figure 14: Global Market Attractiveness by Drug Type, 2022-2032
Figure 15: Global Market Attractiveness by Region, 2022-2032
Figure 16: North America Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 17: North America Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 28: North America Market Attractiveness by Type Of Allergy, 2022-2032
Figure 29: North America Market Attractiveness by Drug Type, 2022-2032
Figure 30: North America Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 32: Latin America Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 40: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 43: Latin America Market Attractiveness by Type Of Allergy, 2022-2032
Figure 44: Latin America Market Attractiveness by Drug Type, 2022-2032
Figure 45: Latin America Market Attractiveness by Country, 2022-2032
Figure 46: Europe Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 47: Europe Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 55: Europe Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 58: Europe Market Attractiveness by Type Of Allergy, 2022-2032
Figure 59: Europe Market Attractiveness by Drug Type, 2022-2032
Figure 60: Europe Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 62: Asia Pacific Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 73: Asia Pacific Market Attractiveness by Type Of Allergy, 2022-2032
Figure 74: Asia Pacific Market Attractiveness by Drug Type, 2022-2032
Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 76: MEA Market Value (US$ Mn) by Type Of Allergy, 2022-2032
Figure 77: MEA Market Value (US$ Mn) by Drug Type, 2022-2032
Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: MEA Market Value (US$ Mn) Analysis by Type Of Allergy, 2017-2032
Figure 83: MEA Market Value Share (%) and BPS Analysis by Type Of Allergy, 2022-2032
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Type Of Allergy, 2022-2032
Figure 85: MEA Market Value (US$ Mn) Analysis by Drug Type, 2017-2032
Figure 86: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032
Figure 88: MEA Market Attractiveness by Type Of Allergy, 2022-2032
Figure 89: MEA Market Attractiveness by Drug Type, 2022-2032
Figure 90: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
